Merck & Co., Inc. (ETR: 6MK)
Germany
· Delayed Price · Currency is EUR
107.20
-0.40 (-0.37%)
Sep 6, 2024, 5:35 PM CET
Merck & Co. Revenue
Revenue (ttm)
$58.31B
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
$809.90K
Employees
72,000
Market Cap
271.14B EUR
Revenue Chart
* This company reports financials in USD.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Apple Inc. | 359.88B |
The Coca-Cola Company | 43.37B |
SAP SE | 32.54B |
Deutsche Telekom AG | 115.96B |
Allianz SE | 102.90B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 60.62B |
Dr. Ing. h.c. F. Porsche AG | 39.56B |
Mercedes-Benz Group AG | 150.08B |
Merck & Co. News
- 8 hours ago - Eighty-eight Corporate Leaders Endorse Harris For Continued 'Strength' Of Democracy, Economy - IBTimes
- 10 hours ago - Why Did Merck Stock Rise 65%? - Forbes
- 1 day ago - What's Going On With Merck Shares Thursday? - Benzinga
- 1 day ago - What's Wrong With Merck's Stock? - The Motley Fool
- 2 days ago - Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 - Wallstreet:Online
- 2 days ago - Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024 - Business Wire
- 2 days ago - Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for the Treatment of Diabetic Macular Edema - Wallstreet:Online
- 2 days ago - Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema - Business Wire